Home Cart Sign in  
Chemical Structure| 4698-11-7 Chemical Structure| 4698-11-7

Structure of 4698-11-7

Chemical Structure| 4698-11-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 4698-11-7 ]

CAS No. :4698-11-7
Formula : C15H13NO
M.W : 223.27
SMILES Code : COC1=CC2=CC=CC=C2NC3=CC=CC=C13
MDL No. :MFCD00101079
InChI Key :ZKHZWXLOSIGIGZ-UHFFFAOYSA-N
Pubchem ID :78424

Safety of [ 4698-11-7 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Computational Chemistry of [ 4698-11-7 ] Show Less

Physicochemical Properties

Num. heavy atoms 17
Num. arom. heavy atoms 12
Fraction Csp3 0.07
Num. rotatable bonds 1
Num. H-bond acceptors 1.0
Num. H-bond donors 1.0
Molar Refractivity 73.74
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

21.26 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.55
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

3.65
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

3.4
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.73
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

3.08
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

3.08

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.98
Solubility 0.0234 mg/ml ; 0.000105 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.79
Solubility 0.0366 mg/ml ; 0.000164 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-5.4
Solubility 0.000883 mg/ml ; 0.00000395 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

Yes
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

Yes
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.07 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<2.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.96

Application In Synthesis of [ 4698-11-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 4698-11-7 ]

[ 4698-11-7 ] Synthesis Path-Downstream   1~5

  • 1
  • [ 4698-11-7 ]
  • [ 917-61-3 ]
  • [ 28721-09-7 ]
YieldReaction ConditionsOperation in experiment
50% [10-METHOXY-5H-DIBENZ (B, 0AZEPINE] (29.9 g, 0.134 mol) was added to 300 ml acetonitrile in a three-neck flask (500 ml) equipped with a mechanical stirring apparatus. The mixture was stirred at room temperature for 15 minutes, and then [NAOCN] (18 g, 0.277 mol) was added, followed by pyridiniump-toluenesulfonate (75 g, 0.3 mol). The mixture was stirred at room temperature for about 4 hours, at which time TLC indicated that the reaction was complete (disappearance of [10-METHOXY-5H-DIBENZ (BAZEPINE).] 30 ml water was added, and the mixture stirred for 15 minutes. The solids were filtered and the filtrate was concentrated under vacuum. The semi-solid residue was triturated with acetone to provide a creamy solid, which was dried at [80] C to provide 18 g (0.068 mol, 50% yield) of [10-METHOXY-5H-DIBENZ [B2FLAZEPINE-5-CARBOXAMIDE (10-METHOXYCARBAMAZEPINE).]
In a three-neck flask (500 ml), equipped with a mechanical stirring apparatus, 15 ml water was introduced, followed by pyridinium bromide (71.75 g, 0.45 mole; Chemadaa' (Nir Yitshak, Israel) ). The mixture was stirred at room temperature [(22 C)] for about 10 minutes. Then 250 ml toluene was added, followed by 50 g (0.224 mol) of [10-METHOXY-5H-] dibenz [[BZF] AZEPINE] (compound of formula (4), wherein R4 is methoxy). [Note: 10-methoxy-5H- dibenz [[B, T] AZEPINE] may be obtained from [IMINOSTILBENE] according to the process disclosed in U. S. Patent No. 5,808, 058. [10-METHOXY-5H-DIBENZ [B FLAZEPINE] also is commercially available from various suppliers, including Zhejiang Jiuzhou Pharmaceutical Co. , Ltd. (Zhejiang, China), and Ningbo Chongyangtang Biologic Tech Co. , Ltd. (Ningbo, China)] [NAOCN] (45 g, 0.69 mol ; OCI Corp. , South Korea) was added and the reaction was mixed for about 7-8 hours at room temperature [(22C).] After [7-8] hours, [125ML] of water was added, and the mixture was stirred for about 15 minutes. The resulting solid carbamate of formula (1), 10-methoxy-5H- dibenz [[B2TAZEPINE-5-CARBOXAMIDE,] was filtered and washed with 50 ml of water. The organic layer was separated and washed with water (2 x [50ML).] In a 500 ml three necked flask, the organic phase from above was introduced, to which the solid carbamate of formula (1) [(10-METHOXY-5H-DIBENZ [B2FLAZEPINE-5-CARBOXAMIDE)] was added to form a slurry. The mixture was heated to 89 C to clarify the solution, and 250 ml of 10% [HC1] was added dropwise with stirring. When thin layer chromatography indicated that the intermediate carbamate of formula (1) had been substantially consumed, the reaction mixture was cooled to room temperature and the mixture was stirred at this temperature for 15-30 minutes. The product, [10-OXO-10,] [11-DIHYDRO-5H-DIBENZ [B2FLAZEPINE-5-CARBOXAMIDE] (oxcarbazepine), was filtered and the crude oxcarbazepine cake was thoroughly washed with water until the pH reached 6-7. The mixture was then washed with toluene (50 ml), and the solids were dried to yield 34.4 g (0.137 mol) crude oxcarbazepine as a yellow-brown powder (yield relative to (2) is [61%).] The crude oxcarbazepine was slurried in 408 ml of boiling 80: 20 isopropanol : water for about 1 hour. The solid was separated by filtration and dried to afford 30.6 g oxcarbazepine [(89%] purification yield). Further purification was carried out in 765 ml of boiling 80: 20 isopropanol: water, hot filtration and cooling to room temperature. Filtration and drying of the solid precipitate afforded 26.5 g of purified oxcarbazepine (yield relative to starting material (2) is 47%, and purification yield is 87%).; The carbamoylation reaction was performed as in Example 1, except that [150] ml toluene was used instead of 250 ml. The resulting solid carbamate of formula (1), 10-methoxy-5H- dibenz [[B2FLAZEPINE-5-CARBOXAMIDE,] was isolated as described in Example 1. In a three necked flask, 330 ml of isopropyl alcohol, 78 ml of 12% HCl, and the solid 10- [METHOXY-SH-DIBENZ [B2FLAZEPINE-S-CARBOXAMIDE] were introduced. The mixture was heated to [78] [- 82 C] for about 1 hour. When TLC indicated that the carbamate of formula (1) was consumed, the reaction mixture was cooled to room temperature and stirred for 1 hour. The separated solids were filtered and washed with water to provide crude 10-oxo-10, [11-DIHYDRO-SH-DIBENZ [BFLAZEPINE-S-] carboxamide (oxcarbazepine), which was purified as described in Example 1. Yield relative to starting material of formula (2) was 43-45%.
With maleic acid; In dichloromethane; at 20 - 45℃; for 6 - 24h; EXAMPLE 1A Preparation of 10-methoxycarbamazepine To a 1 L 4-necked round bottom flask was added 10.0 g (0.045 mol) of 10-methoxyiminostilbene, 150.0 ml of dichloromethane, 37.0 g (0.57 mol) of sodium cyanate and 15.0 g (0.13 moles) of maleic acid and stirred at room temperature. The contents were heated to reflux (40-45 C.) under vigorous stirring for about 6 to about 8 hours. After completion of the reaction (detected by TLC) the reaction mass was filtered and washed with 50.0 ml dichloromethane. The dichloromethane layer was washed with water (50.0 ml*2) and the layers were separated. EXAMPLE 2A Preparation of 10-methoxycarbamazepine 50.0 g (0.224 moles) of 10-methoxyiminostilbene was dissolved in 750.0 ml of dichloromethane. 185.0 g (2.846 moles) of sodium cyanate and 75.0 g (0.65 moles) of maleic acid were added to the above solution at a temperature ranging from about 25 C. to about 30 C. The reaction mass was stirred for about 24 hours. After completion of the reaction (determined by HPLC/TLC) the reaction mass was filtered and washed three times with 100 mL of dichloromethane. The dichloromethane layer was evaporated to get a residue of about 150 g to about 200 g.
With MANDELIC ACID; In dichloromethane;Reflux;Product distribution / selectivity; EXAMPLE-2: Preparation of Oxcarbazepine; a) Preparation of 10-methoxy carbamazepine from 10-methoxyiminostilbene; A suspension of 10 g of 10-methoxyiminostilbene in 250 ml dichloromethane was -30 treated with 17.5 g of sodium cyanate and 24 g of mandelic acid and was heated to reflux for about 6-8 hrs. The reaction mixture was cooled to room temperature and the reaction mixture was washed with distilled water and aqueous sodium bicarbonate and further the organic layer was distilled off completely. The resulting residue was treated with with isopropanol, separated solid was filtered and dried to give g of35 10-methoxy carbamazepine.
Example 5; Preparation of 10-oxo-lOJ l-dihydro-5H-dibenz[6,/]azepine-5-carboxamide (Oxcarbazepine), compound of formula [I]; 10-Methoxyiminostilbene, compound of formula [XX], (100 g) was dissolved in toluene (1000 ml). Sodium cyanate (100 g) and benzoic acid (190 g) were added and the reaction mixture was vigorously stirred and heated at 85-90C for 1O h. After the reaction completion, the reaction mixture was cooled, followed by the addition of aqueous NaOH solution (10%, 800 ml) to pH 11. The reaction mixture was stirred for 3 h at this temperature followed by cooling to 0-50C. The reaction mixture was filtered and washed with toluene and water and dried to give the compound of formula [XXI] (yield = 110 g).
With MANDELIC ACID; In dichloromethane; at 20℃; for 8h;Reflux;Product distribution / selectivity; a) Preparation of 10-methoxy carbamazepine from 10-methoxyiminostilbene A suspension of 10 g of 10-methoxyiminostilbene in 250 ml dichloromethane was treated with 17.5 g of sodium cyanate and 24 g of mandelic acid and was heated to reflux for about 6-8 hrs. The reaction mixture was cooled to room temperature and the reaction mixture was washed with distilled water and aqueous sodium bicarbonate and further the organic layer was distilled off completely. The resulting residue was treated with with isopropanol, separated solid was filtered and dried to give g of 10-methoxy carbamazepine.

  • 2
  • [ 76041-86-6 ]
  • [ 4698-11-7 ]
  • 3
  • [ 590-28-3 ]
  • [ 4698-11-7 ]
  • [ 28721-09-7 ]
  • 4
  • [ 4698-11-7 ]
  • [ 32315-10-9 ]
  • [ 28721-09-7 ]
YieldReaction ConditionsOperation in experiment
85% ) A solution of 66.9 g (0.3 mols) of 10-methoxy-iminostilbene and 34.92 g (0.34 mols) of triethylamine in 800 ml of toluene is gradually added, during 6 hours and at a temperature of 10-15C, with a solution of 32.67 g (0.11 mols) of triphosgene in 300 ml of toluene. After completion of the reaction (disappearance of methoxy-iminostilbene) 200 ml of 30% aqueous ammonia are added gradually, vigorously stirring at room temperature for some hours. After that, the phases are separated, the toluene phase is washed with water and evaporated to dryness under reduced pressure. Yield: 69.0 g (85% on theoretical) of 10-methoxy-N-aminocarbonyl-iminostilbene (V) of purity higher than 95%.
  • 5
  • [ 4698-11-7 ]
  • [ 232951-82-5 ]
  • [ 28721-09-7 ]
YieldReaction ConditionsOperation in experiment
80% To a solution of 10-methoxy-5H-dibenz[b,f]azepine (3; 223.3 mg, 1.0 mmol) in CH2Cl2 (5 mL) at r.t. under argon was added FmocNCO (397.9 mg, 1.5 mmol). The mixture was stirred for 16 h, then piperidine (2.5 mL, 25.2 mmol) and MeOH (13 mL) were added successively. After the removal of MeOH, the residue was extracted with EtOAc. The organic layer was dried over MgSO4 and concentrated in vacuo, and the residue was purified by silica gel column chromatography (EtOAc-hexane, 1:2) to give 8 as a white solid; yield: 213 mg (0.800 mmol, 80%); mp 193-194 C. IR (ATR): 3476, 1666, 1600, 1402, 1133 cm-1. 1H NMR (600 MHz, CDCl3): delta = 7.73 (d, J = 7.3 Hz, 1 H), 7.45 (m, 3 H), 7.35 (m, 1 H), 7.27 (m, 3 H), 6.14 (s, 1 H), 5.20-4.10 (br, 2 H), 3.88 (s, 3H). 13C NMR (150 MHz, CDCl3): delta = 156.8, 156.0, 140.1, 138.5, 135.0, 134.6, 133.0, 130.4, 129.2, 128.2, 128.1, 127.7, 127.6, 127.5, 127.3, 55.4. HRMS (ESI): m/z [M + H]+ calcd for C16H14N2O2: 267.1128; found: 267.1123.
 

Historical Records

Technical Information

Categories